Complementary effects of RNA encoded, extended half-life IL2 and IL7 synergize in modulating T cell responses and antitumoral efficacy

被引：0

作者：

Kranz, Lena ^{[1
]}

Vormehr, Mathias ^{[1
]}

Dieckmann, Jan ^{[2
]}

Lindemann, Claudia ^{[2
]}

Eisel, David ^{[1
]}

Muik, Alexander ^{[1
]}

Fellermeier-Kopf, Sina ^{[1
]}

Gieseke, Friederike ^{[1
]}

Tillmann, Bodo ^{[3
]}

Witzel, Sonja ^{[3
]}

Lepper, Marlen ^{[2
]}

Diken, Mustafa ^{[3
]}

Kreiter, Sebastian ^{[3
]}

Jahndel, Veronika ^{[2
]}

Tureci, Ozlem ^{[2
]}

Sahin, Ugur ^{[2
]}

机构：

[1] BioNTech RNA Pharmaceut, Mainz, Germany

[2] BioNTech SE, Mainz, Germany

[3] TRON Translat Oncol gGmbH, Mainz, Germany

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P620

引用

页数：1

共 5 条

[1] Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
Tritz, Zachariah P.
Ayasou, Katayoun
Wolf, Delaney M.
Owens, Carley A.
Malo, Courtney S.
Himes, Benjamin T.
Fain, Cori E.
Goddery, Emma N.
Yokanovich, Lila T.
Jin, Fang
Hansen, Michael J.
Parney, Ian F.
Wang, Chensu
Moynihan, Kelly D.
Irvine, Darrell J.
Wittrup, K. Dane
Marcano, Rosa M. Diaz
Vile, Richard G.
Johnson, Aaron J.
CANCER IMMUNOLOGY RESEARCH, 2023, 11 (06) : 763 - 776
[2] Alemtuzumab as Anti-Rejection Therapy in Kidney Transplant Patients Induces Homeostatic T Cell Proliferation and Impairs IL7 but Not IL2 Responses.
Bouvy, A.
Hesselink, D.
Klepper, M.
Weimar, W.
Baan, C.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 224 - 224
[3] IL7 and IL15 but not IL2 increase Ag specific effector T cells following dendritic cell based vaccination.
Melchionda, F
Fry, TJ
Mackall, CL
BLOOD, 2002, 100 (11) : 674A - 674A
[4] Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation
Milling, Lauren E.
Garafola, Daniel
Agarwal, Yash
Wu, Shengwei
Thomas, Ayush
Donahue, Nathan
Adams, Josetta
Thai, Nikki
Suh, Heikyung
Irvine, Darrell J.
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01) : 26 - 39
[5] A PHASE 1 SINGLE ASCENDING DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF MDK-703, AN IL-7 MIMETIC WITH EXTENDED HALF-LIFE
Friend, Richard
Baxter, Bryan
Park, Inkyung Angie
Cwirla, Steven
Barrett, Ronald
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A657 - A657

← 1 →